HSD17B13-IN-1 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), with an IC50 of less than 0.1 μM using estradiol as a substrate; it plays an important role in the research of non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH).